多发性骨髓瘤骨病的新药治疗  

Novel agents for multiple myeloma bone disease

作　　者：杨光忠[1] 陈文明(审校)[1] 

机构地区：[1]首都医科大学附属北京朝阳医院血液科北京市多发性骨髓瘤医疗研究中心,100020

出　　处：《白血病．淋巴瘤》2014年第2期123-127,共5页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金面上项目（81172252）

摘　　要：骨髓瘤骨病（MBD）是多发性骨髓瘤患者一个最常见的临床症状,严重影响了患者的生活质量及生存期.恶性浆细胞与其他骨髓细胞之间的相互作用形成微环境,促进肿瘤生长,同时加重骨破坏.双磷酸盐能降低骨髓瘤患者骨相关事件的发生率.然而,此类药物随着累积剂量的增加,将导致一定毒副作用,包括颌骨坏死与肾脏衰竭,限制了其长期应用的可能性.因此,有必要探究骨髓瘤患者骨髓中细胞间的相互作用机制,寻找MBD的治疗新靶点,目前相关新药正在进行临床前或临床试验.文章就多发性MBD新药治疗进展作一综述.Bone disease is a major morbidity factor in patients with multiple myeloma and significantly affects their overall survival. A complex interplay between malignant plasma cells and other marrow cells results in the generation of a microenvironment to enhance both tumor growth and bone destruction. Bisphosphonates have consistently reduced the incidence of skeletal-related events in patients with multiple myeloma. However, their use is burdened with side-effects, including the risks of osteonecrosis of the jaw and kidney failure, suggesting that they should be discontinued after prolonged administration. New molecular targets of cell cross-talk in myeloma bone marrow are therefore under intensive investigation and new drugs are exploring in preclinical and clinical studies of myeloma bone disease. This review would focus on novel agents in myeloma bone disease.

关 键 词：多发性骨髓瘤 骨病 新药 

分 类 号：R733.3[医药卫生—肿瘤]